Peringatan Keamanan

There is no information regarding the acute toxicity or overdose of vilobelimab.

Vilobelimab

DB16416

biotech investigational

Deskripsi

Vilobelimab is a chimeric monoclonal immunoglobulin G4 (IgG4) antibody that binds to the soluble form of human C5a with high affinity. It consists of mouse anti-human complement factor 5a (C5a) monoclonal binding sites (variable regions of heavy and light chain regions) and human gamma 4 heavy chain and light kappa chain constant regions.L45839 In April 2023, the FDA issued an emergency use authorization (EUA) for vilobelimab for the treatment of COVID-19 in hospitalized adults requiring mechanical ventilation or artificial life support. The drug is not yet fully approved for this condition.L45849

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The elimination half-life of vilobelimab following a 4 mg/kg single intravenous dose in healthy subjects was 95 hours.[L45839]
Volume Distribusi No information is available.
Klirens (Clearance) No information is available.

Absorpsi

In healthy subjects who received a single intravenous infusion of vilobelimab ranging from 2 mg/kg to 4 mg/kg, the Cmax showed dose proportionality while the AUC showed greater-than-dose proportionality.L45839 Pre-dose plasma samples were collected in patients with severe COVID-19 pneumonia requiring IMV or ECMO. Following intravenous infusion of vilobelimab 800 mg on Days 1, 2, and 4, the pre-dose geometric mean (geometric CV%) plasma concentration of vilobelimab on Day 8 was 137.9 µg/mL (51%).L45839

Metabolisme

As with other monoclonal antibodies, vilobelimab is expected to undergo nonspecific degradation into small peptides and individual amino acids.

Rute Eliminasi

No information is available.

Interaksi Obat

373 Data
Diethylstilbestrol Diethylstilbestrol may increase the thrombogenic activities of Vilobelimab.
Chlorotrianisene Chlorotrianisene may increase the thrombogenic activities of Vilobelimab.
Conjugated estrogens Conjugated estrogens may increase the thrombogenic activities of Vilobelimab.
Estrone Estrone may increase the thrombogenic activities of Vilobelimab.
Estradiol Estradiol may increase the thrombogenic activities of Vilobelimab.
Dienestrol Dienestrol may increase the thrombogenic activities of Vilobelimab.
Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of Vilobelimab.
Mestranol Mestranol may increase the thrombogenic activities of Vilobelimab.
Estriol Estriol may increase the thrombogenic activities of Vilobelimab.
Estrone sulfate Estrone sulfate may increase the thrombogenic activities of Vilobelimab.
Quinestrol Quinestrol may increase the thrombogenic activities of Vilobelimab.
Hexestrol Hexestrol may increase the thrombogenic activities of Vilobelimab.
Tibolone Tibolone may increase the thrombogenic activities of Vilobelimab.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Vilobelimab.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Vilobelimab.
Polyestradiol phosphate Polyestradiol phosphate may increase the thrombogenic activities of Vilobelimab.
Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Vilobelimab.
Zeranol Zeranol may increase the thrombogenic activities of Vilobelimab.
Equol Equol may increase the thrombogenic activities of Vilobelimab.
Estetrol Estetrol may increase the thrombogenic activities of Vilobelimab.
Promestriene Promestriene may increase the thrombogenic activities of Vilobelimab.
Methallenestril Methallenestril may increase the thrombogenic activities of Vilobelimab.
Epimestrol Epimestrol may increase the thrombogenic activities of Vilobelimab.
Moxestrol Moxestrol may increase the thrombogenic activities of Vilobelimab.
Estradiol acetate Estradiol acetate may increase the thrombogenic activities of Vilobelimab.
Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of Vilobelimab.
Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of Vilobelimab.
Estradiol valerate Estradiol valerate may increase the thrombogenic activities of Vilobelimab.
Biochanin A Biochanin A may increase the thrombogenic activities of Vilobelimab.
Formononetin Formononetin may increase the thrombogenic activities of Vilobelimab.
Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Vilobelimab.
Human immunoglobulin G The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Vilobelimab.
Omalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Vilobelimab.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Vilobelimab.
Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Vilobelimab.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vilobelimab.
Indium In-111 satumomab pendetide The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Vilobelimab.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Vilobelimab.
Trastuzumab The risk or severity of adverse effects can be increased when Trastuzumab is combined with Vilobelimab.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Vilobelimab.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Vilobelimab.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Vilobelimab.
Digoxin Immune Fab (Ovine) The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Vilobelimab.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vilobelimab.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Vilobelimab.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Vilobelimab.
Capromab pendetide The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Vilobelimab.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Vilobelimab.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Vilobelimab.
Natalizumab The risk or severity of adverse effects can be increased when Natalizumab is combined with Vilobelimab.
Palivizumab The risk or severity of adverse effects can be increased when Palivizumab is combined with Vilobelimab.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Vilobelimab.
Bevacizumab The risk or severity of adverse effects can be increased when Bevacizumab is combined with Vilobelimab.
Technetium Tc-99m arcitumomab The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Vilobelimab.
Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Vilobelimab.
Panitumumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Vilobelimab.
Ranibizumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Vilobelimab.
Galiximab The risk or severity of adverse effects can be increased when Galiximab is combined with Vilobelimab.
Pexelizumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Vilobelimab.
Afelimomab The risk or severity of adverse effects can be increased when Afelimomab is combined with Vilobelimab.
Epratuzumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Vilobelimab.
Bectumomab The risk or severity of adverse effects can be increased when Bectumomab is combined with Vilobelimab.
Oregovomab The risk or severity of adverse effects can be increased when Oregovomab is combined with Vilobelimab.
IGN311 The risk or severity of adverse effects can be increased when IGN311 is combined with Vilobelimab.
Adecatumumab The risk or severity of adverse effects can be increased when Adecatumumab is combined with Vilobelimab.
Labetuzumab The risk or severity of adverse effects can be increased when Labetuzumab is combined with Vilobelimab.
Matuzumab The risk or severity of adverse effects can be increased when Matuzumab is combined with Vilobelimab.
Fontolizumab The risk or severity of adverse effects can be increased when Fontolizumab is combined with Vilobelimab.
Bavituximab The risk or severity of adverse effects can be increased when Bavituximab is combined with Vilobelimab.
CR002 The risk or severity of adverse effects can be increased when CR002 is combined with Vilobelimab.
Rozrolimupab The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Vilobelimab.
Hepatitis B immune globulin The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Vilobelimab.
Girentuximab The risk or severity of adverse effects can be increased when Girentuximab is combined with Vilobelimab.
Obiltoxaximab The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Vilobelimab.
XTL-001 The risk or severity of adverse effects can be increased when XTL-001 is combined with Vilobelimab.
NAV 1800 The risk or severity of adverse effects can be increased when NAV 1800 is combined with Vilobelimab.
Briakinumab The risk or severity of adverse effects can be increased when Briakinumab is combined with Vilobelimab.
Otelixizumab The risk or severity of adverse effects can be increased when Otelixizumab is combined with Vilobelimab.
AMG 108 The risk or severity of adverse effects can be increased when AMG 108 is combined with Vilobelimab.
Iratumumab The risk or severity of adverse effects can be increased when Iratumumab is combined with Vilobelimab.
Enokizumab The risk or severity of adverse effects can be increased when Enokizumab is combined with Vilobelimab.
Ramucirumab The risk or severity of adverse effects can be increased when Ramucirumab is combined with Vilobelimab.
Farletuzumab The risk or severity of adverse effects can be increased when Farletuzumab is combined with Vilobelimab.
Veltuzumab The risk or severity of adverse effects can be increased when Veltuzumab is combined with Vilobelimab.
Ustekinumab The risk or severity of adverse effects can be increased when Ustekinumab is combined with Vilobelimab.
Trastuzumab emtansine The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Vilobelimab.
PRO-542 The risk or severity of adverse effects can be increased when PRO-542 is combined with Vilobelimab.
TNX-901 The risk or severity of adverse effects can be increased when TNX-901 is combined with Vilobelimab.
Inotuzumab ozogamicin The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Vilobelimab.
RI 624 The risk or severity of adverse effects can be increased when RI 624 is combined with Vilobelimab.
Stamulumab The risk or severity of adverse effects can be increased when Stamulumab is combined with Vilobelimab.
CT-011 The risk or severity of adverse effects can be increased when CT-011 is combined with Vilobelimab.
Leronlimab The risk or severity of adverse effects can be increased when Leronlimab is combined with Vilobelimab.
Glembatumumab vedotin The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Vilobelimab.
Olaratumab The risk or severity of adverse effects can be increased when Olaratumab is combined with Vilobelimab.
IPH 2101 The risk or severity of adverse effects can be increased when IPH 2101 is combined with Vilobelimab.
TB-402 The risk or severity of adverse effects can be increased when TB-402 is combined with Vilobelimab.
Caplacizumab The risk or severity of adverse effects can be increased when Caplacizumab is combined with Vilobelimab.
IMC-1C11 The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Vilobelimab.
Eldelumab The risk or severity of adverse effects can be increased when Eldelumab is combined with Vilobelimab.

Target Protein

Complement C5 C5

Referensi & Sumber

Artikel (PubMed)
  • PMID: 25433014
    Sun S, Zhao G, Liu C, Fan W, Zhou X, Zeng L, Guo Y, Kou Z, Yu H, Li J, Wang R, Li Y, Schneider C, Habel M, Riedemann NC, Du L, Jiang S, Guo R, Zhou Y: Treatment with anti-C5a antibody improves the outcome of H7N9 virus infection in African green monkeys. Clin Infect Dis. 2015 Feb 15;60(4):586-95. doi: 10.1093/cid/ciu887. Epub 2014 Nov 27.
  • PMID: 31631015
    Jayne D: Complement inhibition in ANCA vasculitis. Nephrol Ther. 2019 Nov;15(6):409-412. doi: 10.1016/j.nephro.2019.04.001. Epub 2019 Oct 17.
  • PMID: 33015643
    Vlaar APJ, de Bruin S, Busch M, Timmermans SAMEG, van Zeggeren IE, Koning R, Ter Horst L, Bulle EB, van Baarle FEHP, van de Poll MCG, Kemper EM, van der Horst ICC, Schultz MJ, Horn J, Paulus F, Bos LD, Wiersinga WJ, Witzenrath M, Rueckinger S, Pilz K, Brouwer MC, Guo RF, Heunks L, van Paassen P, Riedemann NC, van de Beek D: Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial. Lancet Rheumatol. 2020 Dec;2(12):e764-e773. doi: 10.1016/S2665-9913(20)30341-6. Epub 2020 Sep 28.
  • PMID: 34806021
    Bauer M, Weyland A, Marx G, Bloos F, Weber S, Weiler N, Kluge S, Diers A, Simon TP, Lautenschlager I, Grundling M, Jaschinski U, Simon P, Nierhaus A, Moerer O, Reill L, Jorres A, Guo R, Loeffler M, Reinhart K, Riedemann N: Efficacy and Safety of Vilobelimab (IFX-1), a Novel Monoclonal Anti-C5a Antibody, in Patients With Early Severe Sepsis or Septic Shock-A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase IIa Trial (SCIENS Study). Crit Care Explor. 2021 Nov 17;3(11):e0577. doi: 10.1097/CCE.0000000000000577. eCollection 2021 Nov.
  • PMID: 15771587
    Guo RF, Ward PA: Role of C5a in inflammatory responses. Annu Rev Immunol. 2005;23:821-52. doi: 10.1146/annurev.immunol.23.021704.115835.

Contoh Produk & Brand

Produk: 1 • International brands: 0
Produk
  • Gohibic
    Injection • 10 mg/1mL • Intravenous • US

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul